Sign In
Buy PCVX
$52.11
+0.670 (+1.30%)
At Close: Jun 22, 2026
First-in-Human Study Evaluating VAX-A1, a Potential Best-in-Class Vaccine Candidate Designed to Provide Broad Protection Against Disease Caused by Group A Streptococcus
Vaxcyte, Inc. (PCVX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
07:10pm, Tuesday, 12'th May 2026
Vaxcyte, Inc. (PCVX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
04:05pm, Wednesday, 06'th May 2026
Enrollment Now Completed for OPUS-1, OPUS-2 and OPUS-3 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Vaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV Market
10:59pm, Friday, 01'st May 2026
Vaxcyte is evolving from a single-product biotech into a commercial vaccine platform with advanced manufacturing and regulatory alignment. VAX-31, a 31-valent pneumococcal conjugate vaccine, targets b
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
04:05pm, Tuesday, 07'th Apr 2026
SAN CARLOS, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside
OPUS-1 Phase 3 Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines (PCVs) Through Head-to-Head Safety, Tolerability and Immunogenicity Comparisons of VAX-31 with Capva
Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte Advanced VAX-31 High Dose into Comprehensive Phase 3 Adult Program; Topline Data f
Bridgefront Capital LLC Increases Stock Holdings in Vaxcyte, Inc. $PCVX
04:50am, Monday, 16'th Mar 2026
Bridgefront Capital LLC boosted its holdings in shares of Vaxcyte, Inc. (NASDAQ: PCVX) by 127.2% during the undefined quarter, according to its most recent filing with the Securities and Exchange Comm
Citigroup Inc. Sells 116,206 Shares of Vaxcyte, Inc. $PCVX
03:51am, Sunday, 01'st Mar 2026
Citigroup Inc. reduced its stake in shares of Vaxcyte, Inc. (NASDAQ: PCVX) by 27.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 313,078 shares of the company
Vaxcyte, Inc. (PCVX) Q4 2025 Earnings Call Transcript
11:27pm, Tuesday, 24'th Feb 2026
Vaxcyte, Inc. (PCVX) Q4 2025 Earnings Call Transcript
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
04:05pm, Tuesday, 24'th Feb 2026
Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies Underway to Support Planned BLA Submission Topline Safety, To
Vaxcyte, Inc. $PCVX Shares Sold by China Universal Asset Management Co. Ltd.
04:29am, Saturday, 21'st Feb 2026
China Universal Asset Management Co. Ltd. lessened its holdings in shares of Vaxcyte, Inc. (NASDAQ: PCVX) by 28.7% during the third quarter, according to the company in its most recent Form 13F filing
Vaxcyte Spotlights VAX-31 Phase 3 Launch, Eyes Adult BLA by End of Next Year at Biotech Summit
02:05am, Monday, 16'th Feb 2026
Vaxcyte (NASDAQ: PCVX) executives used a presentation at an annual biotech summit to highlight progress across the company's pneumococcal conjugate vaccine (PCV) pipeline, with a particular focus on i
Company Expects to Report Topline Data from OPUS-3 Trial and OPUS-2 Phase 3 Trial Evaluating Concomitant Administration of VAX-31 and a Seasonal Influenza Vaccine in First Half of 2027
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
04:05pm, Tuesday, 10'th Feb 2026
SAN CARLOS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today that it will report financial results for the fourth qu
